XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
License Agreements - Syros (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2022
Jan. 31, 2018
USD ($)
item
Sep. 30, 2022
USD ($)
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
shares
Sep. 30, 2021
USD ($)
Dec. 31, 2018
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
License Agreements                
Fair market long term investments     $ 149,124   $ 149,124     $ 221,266
Unrealized gain (loss) on long term investments     (660) $ (27,450) (72,142) $ (28,394)    
Syros Pharmaceuticals, Inc.                
License Agreements                
Fair market long term investments     600   600     $ 3,100
Unrealized gain (loss) on long term investments     $ (300) $ (900) $ (2,500) $ (6,000)    
Syros Pharmaceuticals, Inc.                
License Agreements                
Number of program targets | item   7            
Syros Pharmaceuticals, Inc. | Maximum                
License Agreements                
Target selection and option exercise fee payment   $ 54,000            
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum                
License Agreements                
Additional milestone payments under the license agreement   50,000            
Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum                
License Agreements                
Additional milestone payments under the license agreement   $ 65,000            
Stock purchase agreement | Syros Pharmaceuticals, Inc.                
License Agreements                
Purchase price of common stock             $ 10,000  
Per share price (In USD per share) | $ / shares             $ 12.61  
Ownership (in shares) | shares     93,753   93,753      
Effected stock split (as a percent) 0.01              
Stock purchase agreement | Syros Pharmaceuticals, Inc. | Pre September 2022 -Stock Split Shares                
License Agreements                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares             800,000  
Amended stock purchase agreement | Syros Pharmaceuticals, Inc.                
License Agreements                
Purchase price of common stock             $ 1,400  
Per share price (In USD per share) | $ / shares             $ 9.55  
Amended stock purchase agreement | Syros Pharmaceuticals, Inc. | Pre September 2022 -Stock Split Shares                
License Agreements                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares             100,000